For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Sanara MedTech Inc. (SMTI) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Sanara MedTech Inc. is a medical technology company specializing in developing and commercializing advanced wound care products and technologies. The company's primary focus is on enhancing patient outcomes through innovative solutions that address the complex needs of wound management and skin care. Sanara MedTech offers a comprehensive suite of products, including antimicrobial wound dressings, collagen-based products, and surgical site management solutions, which are designed to improve healing and reduce infection risks in chronic and acute wounds. Operating primarily in the healthcare sector, Sanara MedTech collaborates with healthcare providers, hospitals, and outpatient facilities, providing them with cutting-edge technologies that support efficient patient care. The company's commitment to research and development ensures that it remains at the forefront of innovation in the medical field, addressing some of the significant challenges faced by clinicians today. Sanara MedTech's contributions to the wound care industry underscore its vital role in the market, as it not only aids in advancing medical practices but also promotes improved quality of life for patients worldwide. This has positioned the company as a key player in the healthcare landscape, catering to the increasing demand for effective wound care solutions.
Earnings Schedule
Checked daily · calendar updated Jul 30| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Jul 23, 2026 | $3.32 | $3.52 +6.0% | — | — |
| Jul 9, 2026 | $0.04 | $-0.02 -150.0% | — | — |
| May 11, 2026 | $-0.22 | $0.04 +118.2% | — | — |
| Mar 24, 2026 | $0.11 | $-0.19 -272.7% | — | — |
| Dec 9, 2025 | $0.18 | $0.38 +111.1% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
Last updated: Jul 30, 2026 8:26am (1h ago)| Filed | Form | Document |
|---|---|---|
| Jul 30, 2026 | 425 | View |
| Jul 30, 2026 | 425 | View |
| Jul 29, 2026 | 425 | View |
| Jul 29, 2026 | 425 | View |
| Jul 29, 2026 | 425 | View |
| Jul 29, 2026 | 425 | View |
| Jul 29, 2026 | 8-K | View |
| Jul 29, 2026 | 425 | View |
| Jun 9, 2026 | 8-K | View |
| Jun 5, 2026 | 4 | View |
| Jun 5, 2026 | 4 | View |
| Jun 5, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Jul 30, 2026 10:07am (just now)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): -4.36
Total Equity: $5.93M
Shares: 8,623,028
Total Debt: $45.97M
Cash: $16.58M
EBITDA: $11.25M
Total Debt: $45.97M
Cash: $16.58M
Revenue: $103.12M
Shares: 8,623,028
Revenue: $103.12M
Revenue: $103.12M
Revenue: $103.12M
Total Equity: $5.93M
Tax Rate: N/A
Equity: $5.93M
Total Debt: $45.97M
Cash: $16.58M
Current Liabilities: $18.63M
Long-Term Debt: $45.97M
Total Debt: $45.97M
Total Equity: $5.93M
Shares: 8,623,028
Shares: 8,623,028
CapEx: -$4.63M
Shares: 8,623,028
Stock Price: $30.25
Net Income: -$37.56M
Income Statement (Annual)
Last updated: Jul 30, 2026 8:26am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $24.1M | $45.8M | $65.0M | $86.7M | $103.1M |
| Cost of Revenue | $2.3M | $6.4M | $7.9M | $8.1M | $7.5M |
| Gross Profit | $21.8M | $39.5M | $57.1M | $78.5M | $95.6M |
| Operating Expenses | $29.2M | $51.7M | $61.4M | $85.2M | $88.3M |
| Operating Income | -$7.4M | -$12.2M | -$4.2M | -$6.7M | $7.3M |
| Net Income | -$8.0M | -$7.9M | -$4.3M | -$9.7M | -$37.6M |
| EBITDA | — | — | — | -$1.8M | $11.3M |
| EPS | $-1.08 | $-1.00 | $-0.52 | $-1.14 | $-4.36 |
| EPS (Diluted) | $-1.09 | $-1.00 | $-0.52 | $-1.14 | $-4.36 |
Balance Sheet (Annual)
Last updated: Jul 30, 2026 8:26am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $18.7M | $9.0M | $5.1M | $15.9M | $16.6M |
| Total Current Assets | $24.6M | $20.6M | $19.0M | $33.3M | $33.5M |
| Total Assets | $36.4M | $61.0M | $73.9M | $88.1M | $72.9M |
| Current Liabilities | $6.0M | $12.8M | $13.8M | $15.3M | $18.6M |
| Long-Term Debt | — | — | $9.1M | $30.7M | $46.0M |
| Total Liabilities | $6.2M | $19.3M | $29.3M | $49.2M | $67.0M |
| Total Equity | $30.2M | $41.7M | $44.6M | $38.9M | $5.9M |
| Retained Earnings | -$15.2M | -$23.4M | -$28.0M | -$37.8M | -$75.3M |
Cash Flow (Annual)
Last updated: Jul 30, 2026 8:26am (1h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$4.8M | -$5.6M | -$3.2M | $-23,784 | $6.8M |
| Capital Expenditure | $-171,867 | $-147,015 | $-265,246 | $-205,848 | -$4.6M |
| Free Cash Flow | -$5.0M | -$5.7M | -$3.5M | $-229,632 | $2.2M |
| Acquisitions (net) | — | — | -$9.9M | — | — |
| Net Debt Issued / (Repaid) | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $18.2M | -$9.7M | -$3.8M | $10.7M | $700,562 |
Growth Trends (YoY %)
Last updated: Jul 30, 2026 8:26am (1h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +89.9% | +41.8% | +33.4% | +19.0% |
| Gross Profit Growth | +80.8% | +44.7% | +37.4% | +21.7% |
| Operating Income Growth | -65.8% | +65.5% | -59.3% | +208.8% |
| Net Income Growth | +0.7% | +45.8% | -124.6% | -288.7% |
| EBITDA Growth | — | — | — | +727.7% |
Industry Benchmarks
Advanced Analysis Forensic deep-dive · three lenses
Character & Durability Scorecard
ext-scorecard step) when a report is run on this ticker.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Narrative Economics
market-narrative step).
Delvantic AI Findings
ai-findings step) when a report is run on this ticker.
GPT Critique
gpt-critique step) after the AI findings above, when a
report is run on this ticker.